Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer

The newly FDA-approved drug, Axitinib, is an effective therapy against RTKs, but it possesses severe adverse effects like hypertension, stomatitis, and dose-dependent toxicity. In order to ameliorate Axitinib’s downsides, the current study is expedited to search for energetically stable and optimize...

Descripción completa

Detalles Bibliográficos
Autores principales: Ejaz, Syeda Abida, Aziz, Mubashir, Fawzy Ramadan, Mohamed, Fayyaz, Ammara, Bilal, Muhammad Sajjad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221949/
https://www.ncbi.nlm.nih.gov/pubmed/37241785
http://dx.doi.org/10.3390/molecules28104044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221949/
https://www.ncbi.nlm.nih.gov/pubmed/37241785
http://dx.doi.org/10.3390/molecules28104044

Ejemplares similares